Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Published on May 26, 2019in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2019.37.15_SUPPL.4012
Thomas Yau43
Estimated H-index: 43
,
Yoon-Koo Kang77
Estimated H-index: 77
(Asan Medical Center)
+ 17 AuthorsChiun Hsu44
Estimated H-index: 44
(NTU: National Taiwan University)
Sources
Abstract
4012Background: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% a...
📖 Papers frequently viewed together
1,800 Citations
873 Citations
2,403 Citations
References0
Newest
Cited By123
Newest
#1Huilin XuH-Index: 7
#2Dedong Cao (WHU: Wuhan University)H-Index: 7
Last. Ximing Xu (WHU: Wuhan University)H-Index: 12
view all 8 authors...
BACKGROUND Immune checkpoint inhibitors (ICI) are increasingly used in hepatocellular carcinoma (HCC) trials. However, the correlations between early endpoints, such as progression free survival (PFS), objective response rate (ORR), and disease control rate (DCR), and overall survival (OS) are unclear. In this study, the correlations between OS and other early endpoints were evaluated in HCC patients who received ICI. METHODS Pubmed and Embase were searched to October 2020. Clinical studies eval...
Source
#1Ahmed KasebH-Index: 29
#2S. Cheenu KappadathH-Index: 13
Last. Bruno C. OdisioH-Index: 12
view all 18 authors...
Source
1 CitationsSource
#2Fabian FinkelmeierH-Index: 16
Last. Oliver WaidmannH-Index: 28
view all 3 authors...
Source
#1Tim F. GretenH-Index: 71
#2Ghassan K. Abou-Alfa (Cornell University)H-Index: 52
Last. Ahmed Kaseb (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 21 authors...
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunothera...
Source
#1Min Luo (Guangxi Medical University)H-Index: 1
#2Yan Lin (Guangxi Medical University)H-Index: 10
Last. Lianying Ge (Guangxi Medical University)H-Index: 2
view all 5 authors...
Background null The protein "human endogenous retrovirus H long terminal repeat-associating 2" (HHLA2), a member of the B7 family, has been linked to cancer progression and immune responses. However, its functional role in hepatocellular carcinoma (HCC) remains unknown. null Methods null Bioinformatics was used to examine the potential roles of HHLA2 in HCC and the molecular pathways involved. Expression of HHLA2 and PD-L1 as well as the density of tumor-infiltrating lymphocytes (TILs) in tumora...
Source
#1Farhan Z. Ilyas (The Ohio State University Wexner Medical Center)
#2Joal D. Beane (The Ohio State University Wexner Medical Center)H-Index: 20
Last. Timothy M. Pawlik (The Ohio State University Wexner Medical Center)H-Index: 118
view all 0 authors...
Hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and gallbladder carcinoma (GBC), are lethal cancers with limited therapeutic options. Curative-intent treatment typically involves surgery, yet recurrence is common and many patients present with advanced disease not amenable to an operation. Immunotherapy represents a promising approach to improve outcomes, but the immunosuppressive tumor microenvironment of the liver characteristic of hepatobiliary cance...
Source
#1Seyda Gunduz (Mayo Clinic)H-Index: 1
#2Gia Saini (Mayo Clinic)H-Index: 1
Last. Rahmi Oklu (Mayo Clinic)H-Index: 33
view all 7 authors...
Source
#1Dmitrii Shek (USYD: University of Sydney)H-Index: 1
#2Scott A. Read (USYD: University of Sydney)H-Index: 11
Last. Golo AhlenstielH-Index: 25
view all 7 authors...
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. A first-line standard of care (SoC), sorafenib results in median overall survival (OS) of 12 months in Child-Pugh class A patients, and 6 months in Child-Pugh class B patients with objective response rates (ORR) not exceeding 19%. These low efficacy rates have driven research on alternative therapeutic options, particularly immune-checkpoint inhibitors (ICIs). We reviewed the response rates (estimat...
2 CitationsSource
#1Alice Boilève (Institut Gustave Roussy)H-Index: 4
#2Marc HilmiH-Index: 4
Last. Cindy Neuzillet (Curie Institute)H-Index: 10
view all 5 authors...
Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) exhibit a poor prognosis with 5-year overall survival rates around 15%, all stages combined. Most of these primary liver malignancies are metastatic at diagnostic, with only limited therapeutic options, relying mainly on systemic therapies. Treatment modalities are different yet partially overlapping between HCC and BTC. The complex molecular profile of BTC yields to several actionable therapeutic targets, contrary to HCC that remain...
1 CitationsSource